KR20090101169A - 리폭신 ａ₄유사체의 결정질 칼륨염 - Google Patents

리폭신 ａ₄유사체의 결정질 칼륨염 Download PDF

Info

Publication number
KR20090101169A
KR20090101169A KR1020097011427A KR20097011427A KR20090101169A KR 20090101169 A KR20090101169 A KR 20090101169A KR 1020097011427 A KR1020097011427 A KR 1020097011427A KR 20097011427 A KR20097011427 A KR 20097011427A KR 20090101169 A KR20090101169 A KR 20090101169A
Authority
KR
South Korea
Prior art keywords
potassium salt
crystalline
crystalline potassium
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097011427A
Other languages
English (en)
Korean (ko)
Inventor
틸로 하크
단야 그로스바흐
가브리엘 빈터
미하엘 산더
볼프강 베크만
클라우스 바르텔
크리스티안 딘터
Original Assignee
바이엘 쉐링 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090101169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 쉐링 파마 악티엔게젤샤프트 filed Critical 바이엘 쉐링 파마 악티엔게젤샤프트
Publication of KR20090101169A publication Critical patent/KR20090101169A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
KR1020097011427A 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염 Ceased KR20090101169A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04
US60/872,830 2006-12-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030409A Division KR20140135847A (ko) 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염

Publications (1)

Publication Number Publication Date
KR20090101169A true KR20090101169A (ko) 2009-09-24

Family

ID=39076610

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097011427A Ceased KR20090101169A (ko) 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염
KR1020167011173A Ceased KR20160054030A (ko) 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염
KR1020147030409A Ceased KR20140135847A (ko) 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167011173A Ceased KR20160054030A (ko) 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염
KR1020147030409A Ceased KR20140135847A (ko) 2006-12-04 2007-12-04 리폭신 ａ₄유사체의 결정질 칼륨염

Country Status (28)

Country Link
US (2) US7906678B2 (enExample)
EP (2) EP3489214A1 (enExample)
JP (1) JP5410984B2 (enExample)
KR (3) KR20090101169A (enExample)
CN (1) CN101553456B (enExample)
AR (1) AR064116A1 (enExample)
AU (1) AU2007327765B2 (enExample)
BR (1) BRPI0719679A2 (enExample)
CA (1) CA2670791C (enExample)
CL (1) CL2007003468A1 (enExample)
CO (1) CO6190608A2 (enExample)
CR (1) CR10837A (enExample)
DO (1) DOP2009000130A (enExample)
EA (1) EA018615B1 (enExample)
EC (1) ECSP099380A (enExample)
IL (1) IL198434A (enExample)
MA (1) MA31079B1 (enExample)
MX (1) MX2009005911A (enExample)
MY (1) MY147951A (enExample)
NO (1) NO20092528L (enExample)
NZ (1) NZ577338A (enExample)
PE (2) PE20120395A1 (enExample)
SV (1) SV2009003286A (enExample)
TN (1) TN2009000167A1 (enExample)
TW (1) TWI415833B (enExample)
UY (1) UY30755A1 (enExample)
WO (1) WO2008068041A1 (enExample)
ZA (1) ZA200904689B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906678B2 (en) * 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
CN102470158A (zh) * 2009-08-27 2012-05-23 默沙东公司 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
EP2958560B1 (en) * 2013-02-21 2019-05-08 Forsyth Dental Infirmary for Children Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs
ES2895062T3 (es) * 2015-03-18 2022-02-17 Forsyth Dental Infirmary For Children Métodos para estabilizar placas ateroscleróticas usando lipoxinas, resolvinas y análogos de las mismas
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2020507761A (ja) 2017-01-31 2020-03-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症系疾患の生化学的エンドタイプを定義するａｌｘ受容体リガンド
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
WO1994029262A1 (en) 1993-06-15 1994-12-22 Brigham & Women's Hospital Lipoxin compounds
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
WO2000054767A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
TR200201244T2 (tr) 1999-11-09 2002-08-21 Alcon, Inc. Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
JP2005516011A (ja) 2001-12-13 2005-06-02 ランバクシー ラボラトリーズ リミテッド 結晶二水化セフニディールカリウム
JP4634716B2 (ja) 2002-03-15 2011-02-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形
DE602004029982D1 (de) 2003-01-30 2010-12-23 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
KR20070088764A (ko) 2005-10-31 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 세프디니어 칼륨염의 결정형
US7906678B2 (en) * 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs

Also Published As

Publication number Publication date
PE20081200A1 (es) 2008-11-06
EP2089350B1 (en) 2018-08-22
JP5410984B2 (ja) 2014-02-05
CL2007003468A1 (es) 2008-07-04
AU2007327765A1 (en) 2008-06-12
IL198434A (en) 2012-09-24
EA200900732A1 (ru) 2009-12-30
MX2009005911A (es) 2009-09-07
CR10837A (es) 2009-07-23
NO20092528L (no) 2009-08-26
CN101553456B (zh) 2013-08-28
US8049035B2 (en) 2011-11-01
CA2670791C (en) 2017-01-03
EP3489214A1 (en) 2019-05-29
TN2009000167A1 (en) 2010-10-18
CO6190608A2 (es) 2010-08-19
ECSP099380A (es) 2009-11-30
SV2009003286A (es) 2009-10-02
US20080182897A1 (en) 2008-07-31
ZA200904689B (en) 2011-10-26
US7906678B2 (en) 2011-03-15
CN101553456A (zh) 2009-10-07
TWI415833B (zh) 2013-11-21
MY147951A (en) 2013-02-15
DOP2009000130A (es) 2009-08-15
KR20140135847A (ko) 2014-11-26
UY30755A1 (es) 2008-07-31
TW200838847A (en) 2008-10-01
CA2670791A1 (en) 2008-06-12
WO2008068041A1 (en) 2008-06-12
KR20160054030A (ko) 2016-05-13
BRPI0719679A2 (pt) 2014-01-14
MA31079B1 (fr) 2010-01-04
NZ577338A (en) 2011-02-25
JP2010511649A (ja) 2010-04-15
AR064116A1 (es) 2009-03-11
EP2089350A1 (en) 2009-08-19
PE20120395A1 (es) 2012-05-23
US20110124910A1 (en) 2011-05-26
EA018615B1 (ru) 2013-09-30
HK1135961A1 (en) 2010-06-18
AU2007327765B2 (en) 2012-04-12
IL198434A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
US8049035B2 (en) Crystalline potassium salt of lipoxin A4 analogs
KR100704142B1 (ko) 사람 퍼옥시좀 증식 활성화 수용체(ＰＰＡＲ)α의 효능제로서의 치환된 페닐프로피온산 유도체
CA2513092C (en) Compounds for the treatment of metabolic disorders
AU2007225208A1 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
AU5188199A (en) Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
CA2169187A1 (en) Use of phenols and phenol derivatives as pharmaceutical agents with a fibrinogen-lowering action
JP2007508382A (ja) Ｐｐａｒモジュレータとしてのフェノキシエーテル誘導体
JP2024122966A (ja) 芳香族化合物およびその医薬用途
HK1135961B (en) Crystalline potassium salt of lipoxin a4 analogs
US20080182901A1 (en) Crystalline acid of lipoxin A4 analogs and method of making
PT88116B (pt) Processo de preparacao de derivados de acido naftalenopropionico uteis como agentes anti-inflamatorios/antialergicos
US20090036530A1 (en) Crystalline acid of lipoxin A4 analogs and method of making
HK1154819A (en) Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid
JP2011520929A (ja) 結晶性の２−（（２ｓ，３ｒ，４ｅ，６ｅ，１０ｅ，１２ｓ）−１３−（４−フルオロフェノキシ）−２，３，１２−トリヒドロキシトリデカ−４，６，１０−トリエン−８−イニルオキシ）酢酸の無水及び水和物形態
KR100806004B1 (ko) 선택적 페록시좀 증식제 활성화 수용체 조절제
JP2520416B2 (ja) ω−〔〔〔５−（置換ベンジルチオ）チアジアゾ−ル−２−イル〕チオメチル〕フエノキシ〕アルキルカルボン酸
WO1981001553A1 (fr) Derives de l'acide oxalylacetique

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090603

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121203

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130617

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140929

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140627

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150113

Appeal identifier: 2014101006084

Request date: 20140929

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141029

PJ0801 Rejection of trial

Patent event date: 20150113

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20150113

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101006084

Request date: 20140929